Interferon beta induces interleukin-10 expression: Relevance to multiple sclerosis

Annals of Neurology

Volumn 40, Issue 4, 1996, Pages 618-627

  Rudick, Richard A ^a   Ransohoff, Richard M ^a   Peppler, Richard ^a   Medendorp, Sharon Vanderbrug ^a   Lehmann, Paul ^b   Alam, John ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTERFERON; BETA1A INTERFERON; INTERLEUKIN 10; RECOMBINANT INTERFERON BETA 1A; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; INTRAMUSCULAR DRUG ADMINISTRATION; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; BASE SEQUENCE; BRAIN; CELL CULTURE TECHNIQUES; DNA PRIMERS; HUMANS; IMMUNITY, CELLULAR; INJECTIONS, INTRAMUSCULAR; INTERFERON-BETA; INTERLEUKIN-10; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS; RNA, MESSENGER;

EID: 0029909221     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410400412     Document Type: Article

References (55)

1. Rudick RA, Goodkin DE, eds. Treatment of multiple sclerosis: trial design, results and future perspectives. London: Springer, 1992
2. The IFNB Multiple Sclerosis Study Group. Interferon β 1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661
3. Paty DW, Li DK, UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis of results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-667
4. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285
5. Durelli L. Bongioanni MR, Cavallo R, et al. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 1994;44:406-413
6. Jacobs LD, Cookfar DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294
7. Sen GC, Ransohoff RM. Interferon-induced antiviral actions and their regulation. Adv Virus Res 1993;42:57-102
8. Rudick RA, Sibley W, Durelli L. Treatment of multiple sclerosis with type I interferons. In: Goodkin DE, Rudick RA, eds. Multiple sclerosis: advances in clinical trial design, treatment, and future perspectives. London: Springer, 1996
9. Panitch HS. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol 1994;36(suppl):S25-S28
10. Rudick RA, Ransohoff RM. Biologic effects of interferons: relevance to multiple sclerosis. Multiple Sclerosis Clin Lab Res 1995;1:S12-S16
11. Chen Y, Kuchroo VK, Inobe J, et al. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994;265:1237-1240
12. Devajyothi C, Kalvakolanu I, Babcock GT, et al. Inhibition of interferon-gamma-induced major histocompatibility complex class II gene transcription by interferon-beta and type beta 1 transforming growth factor in human astrocytoma cells. Definition of cis-element. J Biol Chem 1993;268:18794-18800
13. Bo L, Mork S, Kong PA, et al. Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. J Neuroimmunol 1994;51:135-146
14. Selmaj K, Brosnan CF, Raine CS. Colocalization of lymphocytes bearing gamma delta T-cell receptor and heat shock protein hsp65+ oligodendrocytes in multiple sclerosis. Proc Nat Acad Sci USA 1991;88:6452-6456
15. Traugott U, Reinherz EL, Raine CS. Multiple sclerosis. Distribution of T cells, T cell subsets and la-positive macrophages in lesions of different ages. J Neuroimmunol 1983;4:201-221
16. Yu M, Nishiyama A, Trapp BD, Tuohy VK. Interferon-beta inhibits progression of relapsing-remitting experimental auto-immune encephalomyelitis. J Neuroimmunol 1996;64:91-100
17. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-173
18. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994;76:241-251
19. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. IV. Murine CTL clones produce IL-3 and GM-CSF, the activity of which is masked by the inhibitory action of secreted IFN-gamma. J Immunol 1990;144:548-556
20. Swain SL. Regulation of the development of distinct subsets of CD4+ T cells. Res Immunol 1991;142:14-18
21. Teuscher C, Gasser DL, Woodward SR, Hickey WF. Experimental allergic orchids in mice. VI. Recombinations within the H-2S/H-2D interval define the map position of the H-2-associated locus controlling disease susceptibility. Immunogenetics 1990;32:337-344
22. Mustafa MI, Diener P, Hojeberg B, et al. T cell immunity and interferon-gamma secretion during experimental allergic encephalomyelitis in Lewis rats. J Neuroimmnol 1991;31:165-177
23. Brod SA, Benjamin D, Hafler DA. Restricted T cell expression of IL-2/IFN-gamma mRNA in human inflammatory disease. J Immunol 1991;147:810-815
24. Beck J, Rondot P, Catinot L, et al. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988;78:318-323
25. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis (see comments). N Eng J Med 1991;325:467-472
26. Tsukada N, Miyagi K, Matsuda M, et al. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J Neurol Sci 1991;102:230-234
27. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987;37:1097-1102
28. Rieckmann P, Albrecht M, Kitze B, et al. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-88
29. Correale J, Gilmore W, McMillan M, et al. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J Immunol 1995;154:2959-2968
30. Kennedy MK, Torrance DS, Picha KS, Mohler KM. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 1992;149:2496-2505
31. Rott O, Fleischer B, Cash E. Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 1994;24:1434-1440
32. Moore KW, O'Garra A, de Waal Malefyt R, et al. Interleukin-10. Annu Rev Immunol 1993;11:165-190
33. de Waal Malefyt R, Abrams J, Bennett B, et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-1220
34. Fiorentino DF, Zlotnik A, Mosmann TR, et al. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147:3815-3822
35. Mosmann TR, Moore KW. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today 1991;12:49-53
36. Wang P, Wu P, Anthes JC, et al. Interleukin-10 inhibits interleukin-8 production in human neutrophils. Blood 1994;83:2678-2683
37. Joyce DA, Gibbons DP, Green P, et al. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol 1994;24:2699-2705
38. Itoh K, Inoue T, Ito K, Hirohata S. The interplay of interleukin-10 (IL-10) and interleukin-2 (IL-2) in humoral immune responses: IL-10 synergizes with IL-2 to enhance responses of human B lymphocytes in a mechanism which is different from upregulation of CD25 expression. Cell Immunol 1994;157:478-488
39. Llorente L, Richaud-Patin Y, Fior R, et al. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 1994;37:1647-1655
40. Powrie F, Menon S, Coffman RL. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur J Immunol 1993;23:3043-3049
41. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis (see comments). Cell 1993;75:263-274
42. Wogensen L, Huang X, Sarvetnick N. Leukocyte extravasation into the pancreatic tissue in transgenic mice expressing interleukin 10 in the islets of Langerhans. J Exp Med 1993;178:175-185
43. Lee MS, Wogensen L, Shizuru J, et al. Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction. J Clin Invest 1994;93:1332-1338
44. Ransohoff RM, Devajyothi C, Estes ML, et al. Interferon-beta specifically inhibits interferon-gamma-induced class II major histocompatibility complex gene transcription in a human astrocytoma cell line. J Neuroimmunol 1991;33:103-112
45. Ling PD, Warren MK, Vogel SN. Antagonistic effect of interferon-beta on the interferon-gamma-induced expression of la antigen in murine macrophages. J Immunol 1985;135:1857-1863
46. Mehindate K, al-Daccak R, Schall TJ, Mourad W. Induction of chemokine gene expression by major histocompatibility complex class II ligands in human fibroblast-like synoviocytes. Differential regulation by incerleukin-4 and dexamethasone. J Biol Chem 1994;269:32063-32069
47. Lu H-T, Riley JL, Babcock GT, et al. IFNβ acts downstream of CIITA mRNA accumulation to block MHC class II gene expression in IFN-g-treated cells and requires the 48-kDa DNA-binding protein (ISGF3-g). J Exp Med 1996 (in press)
48. Dayal AS, Jensen MA, Lledo A, Arnason BGW. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology 1995;45:2173-2177
49. Peppler R, Rudick RA, Ransohoff RM. The effects of recombinant human interferon beta on mitogen-driven interferon gamma mRNA accumulation in peripheral blood mononuclear cells. Brain Pathol 1994;4:281 (Abstract)
50. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993;46:145-153
51. Onji M, Yamaguchi S, Toshikazu M, et al. Induction of the interleukin-2 receptor (p55) by interferons. J Interferon Res 1991;11:237-241
52. Antel JP, Arnason BG, Medof ME. Suppressor cell function in multiple sclerosis: correlation with clinical disease activity. Ann Neurol 1979;5:338-342
53. Noronha A, Toscas A, Jensen MA. Contrasting effects of alpha, beta, and gamma interferons on nonspecific supressor function in multiple sclerosis. Ann Neurol 1992;31:103-106
54. Recht M, Borden EC, Knight E. A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma. J lmmunol 1991:147:2617-2623
55. Porrini AM, Gambi D, Reder AT. Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J Neuroimmunol 1995;61:27-34